
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy
Keywords: سرطان غیر سلول کوچک ریه; Gefitinib; Non-small cell lung cancer; Epidermal growth factor receptor; Mutation